{
    "clinical_study": {
        "@rank": "97354", 
        "acronym": "SEED", 
        "arm_group": [
            {
                "arm_group_label": "Huaren peritoneal dialysate", 
                "arm_group_type": "Experimental", 
                "description": "Huaren Peritoneal dialysate CAPD 3-5 times/d"
            }, 
            {
                "arm_group_label": "Baxter Peritoneal Dialysate", 
                "arm_group_type": "Active Comparator", 
                "description": "Baxter Peritoneal dialysate CAPD 3-5 times/d"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the efficacy and safety of Huaren Peritoneal Dialysate and Baxter\n      Peritoneal Dialysate, investigate the proper dialysis dose for Chinese CAPD patients."
        }, 
        "brief_title": "Safety and Efficacy Evaluation of Two Kinds of Peritoneal Dialysate", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Failure,Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a prospective, randomized, parallel, controlled, multi-center clinical study\n      of Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate.It aims to  investigate the\n      proper dialysis dose for Chinese CAPD patients.At the same time,it can evaluate the efficacy\n      and safety of Chinese product Huaren Peritoneal Dialysate and peritoneal dialysis product\n      Baxter Peritoneal Dialysate."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518, male or female\n\n          -  Patients with end stage renal diseases\n\n          -  Dialysis mode: CAPD\n\n          -  Dialysis duration:\u226530 days and \u22646 months\n\n          -  Be capable of implementing home dialysis\n\n          -  Diabetic nephropathy, 3ml/min\u2264 residual renal GFR \u226415ml/min; other renal diseases,\n             3ml/min\u2264 residual renal GFR \u226410ml/min\n\n          -  Sign the written informed consent\n\n        Exclusion Criteria:\n\n          -  Acute renal failure\n\n          -  Planing to receive kidney transplantation in 2 years\n\n          -  Hemodialysis\n\n          -  Exit site infection or tunnel infection\n\n          -  Presenting 2/3 of the following: a. abdominal pain, turbid ascites, with or without\n             fever; b. drainage fluid WBC\uff1e100\u00d7106/L, neutrophil ratio\uff1e50%; c.culture positive/\n             Gram stain positive in drainage fluid;\n\n          -  Anti-HIV positive\n\n          -  Allergic to components of dialysate\n\n          -  Active, residual malignant tumor, or systemic infection, liver cirrhosis, severe\n             congestive heart failure, anemia\uff08Hb<80g/L\uff09,malnutrition\uff08Serum Alb<28g/L\uff09,refractory\n             hypertension\n\n          -  Identified peritoneal high transportation by peritoneal equilibration test (PET)\n\n          -  Extreme body shape (height> 185cm or height <145cm), obesity (BMI \u2265 33kg/m2)\n\n          -  Poor compliance\n\n          -  Pregnant or lactating, women of childbearing age do not agree to use effective\n             contraceptive measures during the trial\n\n          -  Has a history of alcoholism and drug abuse (defined as illegal drugs)\n\n          -  Any circumstances when patients are believed unsuitable for this trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "720", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779557", 
            "org_study_id": "HR-PD-2012", 
            "secondary_id": "ChiCTR-TRC-13003001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Huaren peritoneal dialysate", 
                "description": "Huaren Peritoneal dialysate CAPD 3-5 times/d", 
                "intervention_name": "Huaren Peritoneal Dialysate", 
                "intervention_type": "Drug", 
                "other_name": "Huaren Peritoneal Dialysate"
            }, 
            {
                "arm_group_label": "Baxter Peritoneal Dialysate", 
                "description": "Baxter Peritoneal dialysate CAPD 3-5 times/d", 
                "intervention_name": "Baxter Peritoneal Dialysate", 
                "intervention_type": "Drug", 
                "other_name": "Baxter Peritoneal Dialysate"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "CAPD", 
            "efficacy", 
            "safety", 
            "survival rate"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "link": {
            "description": "The website of PLA general hospital", 
            "url": "http://www.301hospital.com.cn/"
        }, 
        "location": {
            "contact": {
                "email": "china_pd@126.com", 
                "last_name": "ZHOU Jianhui, Doctor", 
                "phone": "+86 010 66935462"
            }, 
            "contact_backup": {
                "email": "xmchen301@126.com", 
                "last_name": "CHEN Xiangmei, Doctor", 
                "phone": "+86 010 66935462"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100853"
                }, 
                "name": "Chinese PLA General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Prospective, Randomized, Parallel, Controlled, Multi-center Clinical Study of Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate", 
        "overall_official": {
            "affiliation": "Chinese PLA General Hospital", 
            "last_name": "CHEN Xiangmei, yes", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "survival rate", 
            "safety_issue": "No", 
            "time_frame": "1,2,3,4,5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779557"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Chen Xiangmei", 
            "investigator_title": "Professor, Chief physician, Academician of  Chinese Academy of Engineering", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "PD technique survival rate, estimated glomerular filtration rate, normalized protein catabolic rate,", 
            "safety_issue": "No", 
            "time_frame": "1,2,3,4,5 years"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}